Literature DB >> 19074868

Negative Regulation of AKT Activation by BRCA1.

Tao Xiang1, Amiko Ohashi, Yuping Huang, Tej K Pandita, Thomas Ludwig, Simon N Powell, Qin Yang.   

Abstract

The breast cancer susceptibility gene 1 (BRCA1) plays a key role in mammary tumorigenesis. However, the reasons why silencing the Brca1 gene leads to tumorigenesis are not clearly understood. We report here that BRCA1 deficiency activates the AKT oncogenic pathway, one of the most common alterations associated with human malignancy. Mutation of Brca1 gene increases the phosphorylation and the kinase activity of AKT. The BRCA1-BRCT domains bind to phosphorylated AKT (pAKT) and lead to its ubiquitination toward protein degradation. BRCA1 mutant cells lacking the BRCT repeats accumulate nuclear pAKT and consequently inactivate the transcription functions of FOXO3a, a main nuclear target of pAKT. Our results show that BRCA1 is a negative regulator of the AKT pathway and imply the significance of the BRCA1/AKT pathway in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074868      PMCID: PMC2605656          DOI: 10.1158/0008-5472.CAN-08-3009

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity.

Authors:  Richard Baer; Thomas Ludwig
Journal:  Curr Opin Genet Dev       Date:  2002-02       Impact factor: 5.578

Review 2.  The phosphoinositide 3-kinase pathway.

Authors:  Lewis C Cantley
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

Review 3.  The many forks in FOXO's road.

Authors:  Hien Tran; Anne Brunet; Eric C Griffith; Michael E Greenberg
Journal:  Sci STKE       Date:  2003-03-04

4.  Tumorigenesis in mice carrying a truncating Brca1 mutation.

Authors:  T Ludwig; P Fisher; S Ganesan; A Efstratiadis
Journal:  Genes Dev       Date:  2001-05-15       Impact factor: 11.361

5.  Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain.

Authors:  José Antonio Rodriguez; Wendy W Y Au; Beric R Henderson
Journal:  Exp Cell Res       Date:  2004-02-01       Impact factor: 3.905

6.  BRCT repeats as phosphopeptide-binding modules involved in protein targeting.

Authors:  Isaac A Manke; Drew M Lowery; Anhco Nguyen; Michael B Yaffe
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

7.  The BRCT domain is a phospho-protein binding domain.

Authors:  Xiaochun Yu; Claudia Christiano Silva Chini; Miao He; Georges Mer; Junjie Chen
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

8.  Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity.

Authors:  Yongxian Ma; Changyan Hu; Anna T Riegel; Saijun Fan; Eliot M Rosen
Journal:  Mol Endocrinol       Date:  2007-05-15

9.  A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle.

Authors:  Emma Shtivelman; Joshua Sussman; David Stokoe
Journal:  Curr Biol       Date:  2002-06-04       Impact factor: 10.834

10.  Extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus.

Authors:  Tiho Miralem; Hava Karsenty Avraham
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

View more
  63 in total

1.  Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway.

Authors:  Y Jia; W Song; F Zhang; J Yan; Q Yang
Journal:  Oncogene       Date:  2012-06-04       Impact factor: 9.867

Review 2.  Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development.

Authors:  W-L Yang; X Zhang; H-K Lin
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

3.  Akt is negatively regulated by the MULAN E3 ligase.

Authors:  Seunghee Bae; Sun-Yong Kim; Jin Hyuk Jung; Yeongmin Yoon; Hwa Jun Cha; Hyunjin Lee; Karam Kim; Jongran Kim; In-Sook An; Jongdoo Kim; Hong-Duck Um; In-Chul Park; Su-Jae Lee; Seon Young Nam; Young-Woo Jin; Jae Ho Lee; Sungkwan An
Journal:  Cell Res       Date:  2012-03-13       Impact factor: 25.617

4.  Charting the landscape of tandem BRCT domain-mediated protein interactions.

Authors:  Nicholas T Woods; Rafael D Mesquita; Michael Sweet; Marcelo A Carvalho; Xueli Li; Yun Liu; Huey Nguyen; C Eric Thomas; Edwin S Iversen; Sylvia Marsillac; Rachel Karchin; John Koomen; Alvaro N A Monteiro
Journal:  Sci Signal       Date:  2012-09-18       Impact factor: 8.192

5.  The significance of SUMOylation of angiogenic factors in cancer progression.

Authors:  Mei Wang; Xiaodong Jiang
Journal:  Cancer Biol Ther       Date:  2018-09-27       Impact factor: 4.742

6.  PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.

Authors:  Carole Beck; José Manuel Rodriguez-Vargas; Christian Boehler; Isabelle Robert; Vincent Heyer; Najat Hanini; Laurent R Gauthier; Agnès Tissier; Valérie Schreiber; Mikael Elofsson; Bernardo Reina San Martin; Françoise Dantzer
Journal:  Cell Death Differ       Date:  2018-11-15       Impact factor: 15.828

Review 7.  Mapping the protein-protein and genetic interactions of cancer to guide precision medicine.

Authors:  Mehdi Bouhaddou; Manon Eckhardt; Zun Zar Chi Naing; Minkyu Kim; Trey Ideker; Nevan J Krogan
Journal:  Curr Opin Genet Dev       Date:  2019-07-06       Impact factor: 5.578

8.  Progesterone receptor A stability is mediated by glycogen synthase kinase-3β in the Brca1-deficient mammary gland.

Authors:  Shaohui Wang; Ying Li; Pang-Hung Hsu; Sou-Ying Lee; Yoon Kim; Eva Y-H P Lee
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

9.  AKT regulates BRCA1 stability in response to hormone signaling.

Authors:  Andrew C Nelson; Traci R Lyons; Christian D Young; Kirk C Hansen; Steven M Anderson; Jeffrey T Holt
Journal:  Mol Cell Endocrinol       Date:  2010-01-18       Impact factor: 4.102

10.  Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

Authors:  Ashish Juvekar; Laura N Burga; Hai Hu; Elaine P Lunsford; Yasir H Ibrahim; Judith Balmañà; Anbazhagan Rajendran; Antonella Papa; Katherine Spencer; Costas A Lyssiotis; Caterina Nardella; Pier Paolo Pandolfi; José Baselga; Ralph Scully; John M Asara; Lewis C Cantley; Gerburg M Wulf
Journal:  Cancer Discov       Date:  2012-08-22       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.